Shield Therapeutics News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

21.11.24	Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven (EQS Group)
11.11.24	Hardman & Co Video Event: Shield Therapeutics (STX) Investor Forum (EQS Group)
11.09.24	Hardman & Co Research on Shield Therapeutics (STX): Focusing on successful execution (EQS Group)
23.05.24	Hardman & Co: Shield Therapeutics (STX): Cash management is key (EQS Group)
15.11.23	Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team (EQS Group)
25.07.23	Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering (EQS Group)
17.05.23	Hardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q23 Accrufer prescriptions (EQS Group)
23.01.23	Hardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capital (EQS Group)
13.01.23	Hardman & Co Research: Shield Therapeutics (STX) - Positioned for growth and profitability (EQS Group)
15.09.22	Hardman & Co Research on Shield Therapeutics (STX): Accrufer momentum building (EQS Group)
12.08.22	Hardman & Co: Q&A on Shield Therapeutics (STX): Upside potential is enormous (EQS Group)
26.07.22	Hardman & Co Research: Shield Therapeutics (STX): Looking to accelerate positive signals in the US (EQS Group)
02.03.22	Hardman & Co Research: Shield Therapeutics (STX) - PBMs have bought in to Accrufer (EQS Group)
02.09.19	Hardman & Co Research: Shield Therapeutics (STX): FDA approval ushers in a new era for Shield (EQS Group)
05.08.19	Hardman & Co Research: Shield Therapeutics (STX) FDA approval opens door to major US opportunity (EQS Group)
13.05.19	Hardman & Co Research: Shield Therapeutics (STX): All in the execution (EQS Group)
28.01.19	Hardman & Co Research: Shield Therapeutics (STX): Cast-iron investment (EQS Group)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V